Bannerbild German Brest Group

ASCO: GeparNuevo Presentation

04.06.2018

GeparNuevo Results of primary objective were presented at ASCO 2018: Durvalumab increases the pCR rate in TNBC patients.

/wAssets/docs/GeparNuevo/2018_ASCO_GeparNUEVO.pdf

News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd